Generic Name and Formulations:
Mesalamine 250mg, 500mg; controlled-rel caps.
Shire US, Inc.
Indications for PENTASA:
Mildly-to-moderately active ulcerative colitis.
Swallow whole; may open caps and sprinkle entire contents onto applesauce or yogurt, consume immediately. 1g four times daily for up to 8 weeks.
Discontinue if acute intolerance syndrome is suspected. Atopic dermatitis or eczema: may have more severe photosensitivity reactions. Renal disease; monitor SCr, BUN, proteinuria. Hepatic impairment. Pregnancy (Cat.B). Nursing mothers.
May interfere with urinary normetanephrine test by liquid chromatography; consider alternative assay.
Diarrhea, headache, nausea, abdominal pain, dyspepsia, vomiting, rash; nephrotoxicity.
Caps 250mg—240; 500mg—120
Clinical Pain Advisor Articles
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Reducing Mortality After Overdose: Is Treatment for Opioid Use Disorder Effective?
- A Physician's Guide to Incorporating Patient Spirituality in Practice
- Low Literacy Self-Management Program for Chronic Pain May Be Effective
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- The Challenge of Compassion in Modern Healthcare Settings
- Republican Opposition to Obamacare: What's Done, What's to Come
- Lowering Default Pill Counts in EMRs May Effectively Reduce Postoperative Opioid Prescription Numbers
- Steps Taken to Increase Use of Electronic Tools in Medicine
- Daily and Retrospective Pain Measurements Comparable in Hip Osteoarthritis